New drug aimed at stopping lung rejection in transplant patients

NCT ID NCT06948097

Recruiting now Disease control Sponsor: National Heart, Lung, and Blood Institute (NHLBI) Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Aug 14, 2026 · Updated 35 times

Summary

This early-stage trial tests a drug called fostamatinib in 30 adults who have developed donor-specific antibodies after a lung transplant. These antibodies can attack the new lung and raise the risk of death. Participants take fostamatinib or a placebo for 8 weeks, along with their usual care, to see if the drug is safe and tolerable. The goal is to find a way to prevent rejection and improve long-term survival.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: fostamatinib
What this could lead to: If it works, this could point toward a new way to prevent lung transplant rejection and improve survival for patients with donor-specific antibodies.
What could go wrong: This is a very early Phase 1 trial with only 30 people, focused on safety. It may not show benefit, and the drug could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for LUNG TRANSPLANT REJECTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

transplant rejection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

LUNG TRANSPLANTATION

Contacts and locations

Locations

Inova Health System Foundation
RECRUITING

Falls Church, Virginia, 22042, United States
Johns Hopkins University School of Medicine
RECRUITING

Baltimore, Maryland, 21224, United States
Stanford University School of Medicine
RECRUITING

Stanford, California, 94305, United States
University of Utah Health
RECRUITING

Salt Lake City, Utah, 84132, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.